News Release

Role of the gut barrier in colorectal cancer treatment

“Herein we discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery”

Peer-Reviewed Publication

Impact Journals LLC

The gut barrier as a gatekeeper in colorectal cancer treatment

image: 

Figure 1: Graphical abstract.
Surgery and anastomotic leak (AL) weaken the gut barrier function, which promotes the dissemination and implantation of colorectal cancer cells in the peritoneal cavity and distant organs. A disrupted gut barrier leads to intestinal and systemic inflammation that promote carcinogenesis and decrease survival. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ) by 5-aminosalicylate (5-ASA) and short-chain fatty acids, derived from bacterial fermentation of dietary fibers, reinforces the gut barrier, prevents AL, decreases inflammation, and ultimately improves oncological outcomes. Abbreviations: TNF-α: tumor necrosis factor alpha; IL1β: interleukin 1 beta; IL17A/F: interleukin 17 A/F; MIP-1α: macrophage inflammatory protein 1 alpha; MIP-2: macrophage inflammatory protein 2; MCP-1: monocyte chemoattractant protein 1; IL-5: interleukin 5; IL-10: interleukin 10; IFN-γ: interferon gamma; LCN2: lipocalin 2. Green arrows indicate promotion/stimulation, red arrows indicate inhibition/prevention. Created with https://www.biorender.com/.

view more 

Credit: 2024 Hajjar et al.

“Herein we discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery.”

BUFFALO, NY- August 19, 2024 – A new review was published in Oncotarget's Volume 15 on August 14, 2024, entitled, “The gut barrier as a gatekeeper in colorectal cancer treatment.”

Colorectal cancer (CRC) is highly prevalent and a major cause of cancer-related deaths worldwide. The primary curative treatment for CRC is surgical resection of the affected bowel segment. However, postoperative complications often include a weakened gut barrier and the dissemination of bacterial proinflammatory lipopolysaccharides.

Researchers Roy Hajjar, Carole Richard, and Manuela M. Santos from Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Québec; Centre hospitalier de l’Université de Montréal (CHUM), Québec; Université de Montréal, Québec; and Institut du cancer de Montréal, Québec, discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery.

“We and others have shown in the last few years that gut microbiota influences the healing process of the bowel and the restoration of the gut barrier after surgery.”

The researchers further elaborate on the restoration of gut barrier function in CRC patients and how this potentially impacts the dissemination and implantation of CRC cells in extracolonic tissues, thereby contributing to worse survival outcomes after surgery.

“Based on our recent work, we believe that weakened gut barrier function, namely due to poor healing after surgery, leads to persistent systemic low-grade inflammation and a higher risk of local and systemic cancer recurrence.” 

Continue reading: DOI: https://doi.org/10.18632/oncotarget.28634 

Correspondence to - Roy Hajjar - roy.hajjar@umontreal.ca

Video short - https://www.youtube.com/watch?v=HgWx_11K6Kw

Keywords: colorectal cancer, gut microbiome, gut barrier, colorectal surgery, anastomotic leak

Click here to sign up for free Altmetric alerts about this article.

About Oncotarget:

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact media@impactjournals.com.

Oncotarget Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.